Recent Development of Ruthenium Complexes for Photochemotherapy (PCT) Applications

View at publisher Summarise with VIRAT
Authors: Kelli Hummel, Claudia Turró, Jeremy J. Kodanko
Cited by: 0
References: 84

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

The increasing rates of cancer and common development of resistance to traditional platinum-based chemotherapeutics have inspired researchers to explore other treatment alternatives, particularly photoactive transition metal complexes. Ru(ii) complexes are a particular area of interest due to their versatile photochemical qualities. Upon light irradiation, photodynamic therapy (PDT) agents generate reactive oxygen species (ROS) to induce cell death. Photochemotherapy (PCT) agents, however, release a biologically active ligand or metal complex upon light irradiation while remaining inactive in the dark. Both PDT and PCT agents are attractive alternatives to traditional therapeutics due to their spatiotemporally controlled activation with light, limiting side effects. To address some of the limitations discovered with PDT agents, Ru(ii) PCT compounds have been developed to be generally cytotoxic to cancer cells and to target specific enzymes and subcellular locations to increase specificity for cancer cells.

Fields of Study & Subjects

Metal complexes synthesis and properties Photodynamic Therapy Research Studies Nanoplatforms for cancer theranostics

Publication details

Journal / source
Royal Society of Chemistry eBooks
Pages
68–107
Publication date
25 March 2026
Language
EN
Document type
Book chapter